A Phase I Clinical Trial of Recombinant Herpes Zoster Vaccine (CHO Cell)

NCT07633197 | Enrolling By Invitation Phase 1 DMC

• 1 other identifier: B2005-F20250120-1
• Study Type: interventional
• Target: 120
• Locations: 1 country
• Sites: 1

Brief Summary

To evaluate the safety and tolerability of different dosages of recombinant zoster vaccine (CHO cell) when administered to adults aged 40 years and older.

Conditions

Herpes

Outcome Measures

Primary Outcomes (2)

• Adverse Events/Reactions

  14/30 days after injection

• Incidence of adverse events/reactions after administration

  14days and 30 days after administration

Secondary Outcomes (2)

• IgG Antibody and VZV antibody

  15/30 days after full immunization

• Cellular immune response

  15 days after full immunization

Study Arms (3)

Experimental: BCHT Recombinant Zoster Vaccine vaccine

EXPERIMENTAL

Biological: Recombinant Herpes Zoster Vaccine

Adjuvant placebo

PLACEBO COMPARATOR

Biological: adjuvant placebo

placebo：Sodium Chloride Injection

PLACEBO COMPARATOR

Biological: Placebo

Interventions

Recombinant Herpes Zoster Vaccine BIOLOGICAL

This product is for intramuscular injection only, with the deltoid muscle of the upper arm as the preferred vaccination site. The immunization schedule consists of two doses at 0.5 ml per dose, and the second dose shall be administered two months apart from the first dose.

Experimental: BCHT Recombinant Zoster Vaccine vaccine

adjuvant placebo BIOLOGICAL

This product is for intramuscular injection only, with the deltoid muscle of the upper arm as the preferred vaccination site. The immunization schedule consists of two doses at 0.5 ml per dose, and the second dose shall be administered two months apart from the first dose.

Adjuvant placebo

Placebo BIOLOGICAL

This product is for intramuscular injection only, with the deltoid muscle of the upper arm as the preferred vaccination site. The immunization schedule consists of two doses at 0.5 ml per dose, and the second dose shall be administered two months apart from the first dose.

placebo：Sodium Chloride Injection

Eligibility Criteria

• Age: 40 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Participants are aged ≥40 years on the day of enrollment and can provide legal identity documents;
• The participant voluntarily agrees to take part in the trial and is capable of fully understanding and signing the informed consent form;
• The participant is able to comply with the requirements specified in the clinical trial protocol.

You may not qualify if:

• Axillary body temperature \>37.3°C on the day of enrollment\*;
• Subjects with a prior history of herpes zoster, or having had close contact with patients with chickenpox/herpes zoster within 30 days prior to enrollment;
• Subjects with previous vaccination history of chickenpox or herpes zoster vaccine;
• Subjects allergic to any component of the investigational vaccine (Varicella-Zoster Virus glycoprotein E, BK-02 adjuvant, dipotassium hydrogen phosphate trihydrate, sodium dihydrogen phosphate monohydrate, sucrose, Polysorbate 80), or with a history of severe hypersensitivity to any drugs or vaccines;
• Confirmed or suspected immunosuppression or immunodeficiency disorders induced by underlying diseases or immunosuppressive/cytotoxic therapies, including but not limited to subjects diagnosed with immunodeficiency diseases, malignant tumors, HIV infection, leukemia, lymphoma, Hodgkin's disease, or compromised immunity resulting from organ and bone marrow transplantation;
• Subjects with asplenia or functional asplenia, or autoimmune diseases such as Hashimoto's thyroiditis, vitiligo, rheumatoid arthritis, ankylosing spondylitis;
• Subjects suffering from severe illnesses or potential severe underlying diseases that may interfere with or prevent trial completion (e.g., pulmonary heart disease, pulmonary edema, uncontrolled hypertension despite medication: for participants aged 40-59 years, systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg; for participants aged ≥60 years, systolic blood pressure ≥150 mmHg and/or diastolic blood pressure ≥100 mmHg, severe hepatic and renal diseases, complicated diabetes mellitus, severe cardiovascular diseases, etc.);
• Subjects presenting with acute illnesses (e.g., acute upper respiratory tract infection accompanied by fever, dyspnea and other symptoms) within 3 days before vaccination, or in acute exacerbation phase of chronic diseases, or receiving antipyretic, analgesic or anti-allergy medications\*;
• Subjects who received immunosuppressive therapy within 6 months prior to vaccination or plan to receive such therapy from enrollment through 1 month after completion of full-course immunization (e.g., systemic glucocorticoids administered for ≥14 consecutive days at a daily dose of ≥2 mg/kg or ≥20 mg prednisone or equivalent prednisone dosage; topical steroids including inhalants, nasal sprays, intra-articular injections, eye drops and ointments are excluded); subjects administered long-acting immunomodulatory agents (e.g., infliximab) within 6 months before the first vaccination or scheduled to receive such agents from enrollment to 1 month after full vaccination completion;
• Subjects receiving whole blood, plasma or immunoglobulin transfusion within 3 months prior to vaccination or planning to receive such treatments from enrollment through 1 month after completion of full-course immunization;
• Females of childbearing age planning pregnancy during the trial, or who are pregnant (positive pregnancy test result) or breastfeeding; Subjects with a medical history of thrombocytopenia or other coagulation disorders contraindicating intramuscular injection;
• Subjects with clinically significant abnormal findings in laboratory tests or electrocardiogram confirmed by a clinician before the first vaccine dose;
• Subjects with personal or family history of convulsion, epilepsy, encephalopathy (e.g., cerebral nerve tissue damage caused by congenital cerebral dysplasia, craniocerebral trauma, brain tumor, cerebral hemorrhage, cerebral infarction except lacunar infarction and cerebral infarction without sequelae, intracranial infection, chemical drug poisoning, etc.), psychiatric disorders or other severe neurological diseases;
• Subjects who received live attenuated vaccines within 14 days before vaccination, or recombinant protein vaccines/inactivated vaccines within 7 days before vaccination\*;
• Subjects who have used any investigational or unapproved products (drugs, biological products or medical devices) within 3 months prior to vaccination or intend to use such products during the trial period;

Sponsors & Collaborators

• Changchun BCHT Biotechnology Co.: lead

Study Sites (1)

Henan CDC

Zhengzhou, Henan, China

Location

MeSH Terms

Conditions

Herpes Simplex

Condition Hierarchy (Ancestors)

Herpesviridae Infections; DNA Virus Infections; Virus Diseases; Infections; Skin Diseases, Viral; Skin Diseases, Infectious; Skin Diseases; Skin and Connective Tissue Diseases

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 3, 2026
• First Posted: June 8, 2026
• Study Start: May 28, 2026
• Primary Completion (Estimated): December 28, 2026
• Study Completion (Estimated): November 30, 2027
• Last Updated: June 8, 2026

Record last verified: 2026-06

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)